share_log
Reuters ·  Jan 13 11:30
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations From Phase 1/2 Clinical Trial of Ocu400 —a Novel Modifier Gene Therapy for Retinitis Pigmentosa
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 412
Write a comment